loader
Please Wait
Applying Filters...

Annual Sales of Ferric Carboxymaltose reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

Menu
$ API Ref.Price (USD/KG) : 10,449Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 7Injectafer

PharmaCompass
Left Arrow
Right Arrow

01

Brand Name : Injectafer

Ferric Carboxymaltose

arrow
BioJapan 2024
Not Confirmed

Brand Name : Injectafer

arrow
BioJapan 2024
Not Confirmed

Ferric Carboxymaltose

Main Therapeutic Indication : Hematology

Currency : USD

2020 Revenue in Millions : 410

2019 Revenue in Millions : 456

Growth (%) : -10

blank

02

Brand Name : Injectafer

Ferric Carboxymaltose

arrow
BioJapan 2024
Not Confirmed

Brand Name : Injectafer

arrow
BioJapan 2024
Not Confirmed

Ferric Carboxymaltose

Main Therapeutic Indication : Hematology

Currency : USD

2021 Revenue in Millions : 672

2020 Revenue in Millions : 407

Growth (%) : 78

blank

03

Brand Name : Injectafer

Ferric Carboxymaltose

arrow
BioJapan 2024
Not Confirmed

Brand Name : Injectafer

arrow
BioJapan 2024
Not Confirmed

Ferric Carboxymaltose

Main Therapeutic Indication : Hematology

Currency : USD

2022 Revenue in Millions : 404

2021 Revenue in Millions : 672

Growth (%) : -40

blank

04

Brand Name : Injectafer

Ferric Carboxymaltose

arrow
BioJapan 2024
Not Confirmed

Brand Name : Injectafer

arrow
BioJapan 2024
Not Confirmed

Ferric Carboxymaltose

Main Therapeutic Indication : Hematology

Currency : USD

2023 Revenue in Millions : 340

2022 Revenue in Millions : 404

Growth (%) : -5

blank

05

Brand Name : Injectafer

Ferric Carboxymaltose

arrow
BioJapan 2024
Not Confirmed

Brand Name : Injectafer

arrow
BioJapan 2024
Not Confirmed

Ferric Carboxymaltose

Main Therapeutic Indication : Blood Disorders

Currency : USD

2017 Revenue in Millions : 214

2016 Revenue in Millions : 291

Growth (%) : -27

blank

06

Brand Name : Injectafer

Ferric Carboxymaltose

arrow
BioJapan 2024
Not Confirmed

Brand Name : Injectafer

arrow
BioJapan 2024
Not Confirmed

Ferric Carboxymaltose

Main Therapeutic Indication : Blood Disorders

Currency : USD

2018 Revenue in Millions : 387

2017 Revenue in Millions : 200

Growth (%) : 93%

blank

07

Brand Name : Injectafer

Ferric Carboxymaltose

arrow
BioJapan 2024
Not Confirmed

Brand Name : Injectafer

arrow
BioJapan 2024
Not Confirmed

Ferric Carboxymaltose

Main Therapeutic Indication : Hematology

Currency : USD

2019 Revenue in Millions : 452

2018 Revenue in Millions : 400

Growth (%) : 13

blank